28351298|t|Aberrant gene - specific DNA methylation signature analysis in cervical cancer
28351298|a|Multicomponent molecular modifications such as DNA methylation may offer sensitive and specific cervical intraepithelial neoplasia and cervical cancer biomarkers. In this study, we tested cervical tissues at various stages of tumor progression for 5-methylcytosine and 5-hydroxymethylcytosine levels and also DNA promoter methylation profile of a panel of genes for its diagnostic potential. In total, 5-methylcytosine, 5-hydroxymethylcytosine, and promoter methylation of 33 genes were evaluated by reversed-phase high-performance liquid chromatography, enzyme-linked immunosorbent assay based technique, and bisulfate-based next generation sequencing. The 5-methylcytosine and 5-hydroxymethylcytosine contents were significantly reduced in squamous cell carcinoma and receiver operating characteristic curve analysis showed a significant difference in (1) 5-methylcytosine between normal and squamous cell carcinoma tissues (area under the curve = 0.946) and (2) 5-hydroxymethylcytosine levels among normal, squamous intraepithelial lesions and squamous cell carcinoma. Analyses of our next generation sequencing results and data from five independent published studies consisting of 191 normal, 10 low-grade squamous intraepithelial lesions, 21 high-grade squamous intraepithelial lesions, and 335 malignant tissues identified a panel of nine genes (ARHGAP6, DAPK1, HAND2, NKX2-2, NNAT, PCDH10, PROX1, PITX2, and RAB6C) which could effectively discriminate among the various groups with sensitivity and specificity of 80%-100% (p < 0.05). Furthermore, 12 gene promoters (ARHGAP6, HAND2, LHX9, HEY2, NKX2-2, PCDH10, PITX2, PROX1, TBX3, IKBKG, RAB6C, and DAPK1) were also methylated in one or more of the cervical cancer cell lines tested. The global and gene - specific methylation of the panel of genes identified in our study may serve as useful biomarkers for the early detection and clinical management of cervical cancer.
28351298	0	8	Aberrant	T080	C0443127
28351298	9	13	gene	T028	C0017337
28351298	16	24	specific	T080	C0205369
28351298	25	40	DNA methylation	T044	C0376452
28351298	51	59	analysis	T062	C0936012
28351298	63	78	cervical cancer	T191	C4048328
28351298	94	103	molecular	T080	C1521991
28351298	104	117	modifications	T169	C0392747
28351298	126	141	DNA methylation	T044	C0376452
28351298	152	161	sensitive	T169	C0332324
28351298	166	174	specific	T080	C0205369
28351298	175	209	cervical intraepithelial neoplasia	T191	C0206708
28351298	214	229	cervical cancer	T191	C4048328
28351298	230	240	biomarkers	T123	C0041366
28351298	250	255	study	T062	C2603343
28351298	260	266	tested	T169	C0039593
28351298	267	275	cervical	T029	C0027530
28351298	276	283	tissues	T024	C0040300
28351298	287	294	various	T081	C0439064
28351298	295	301	stages	T079	C1306673
28351298	305	322	tumor progression	T191	C0178874
28351298	327	343	5-methylcytosine	T114,T123	C0049308
28351298	348	371	5-hydroxymethylcytosine	T109	C0049241
28351298	372	378	levels	T080	C0441889
28351298	388	391	DNA	T114,T123	C0012854
28351298	392	400	promoter	T028	C0314621
28351298	401	412	methylation	T044	C0376452
28351298	413	420	profile	T059	C1979963
28351298	435	440	genes	T028	C0017337
28351298	449	459	diagnostic	T169	C0348026
28351298	460	469	potential	T080	C3245505
28351298	481	497	5-methylcytosine	T114,T123	C0049308
28351298	499	522	5-hydroxymethylcytosine	T109	C0049241
28351298	528	536	promoter	T028	C0314621
28351298	537	548	methylation	T044	C0376452
28351298	555	560	genes	T028	C0017337
28351298	579	632	reversed-phase high-performance liquid chromatography	T059	C0008562
28351298	634	667	enzyme-linked immunosorbent assay	T059	C0014441
28351298	674	683	technique	T169	C0449851
28351298	689	731	bisulfate-based next generation sequencing	T063	C2936622
28351298	737	753	5-methylcytosine	T114,T123	C0049308
28351298	758	781	5-hydroxymethylcytosine	T109	C0049241
28351298	796	809	significantly	T078	C0750502
28351298	810	817	reduced	T080	C0392756
28351298	821	844	squamous cell carcinoma	T191	C0007137
28351298	849	888	receiver operating characteristic curve	T081	C0034772
28351298	889	897	analysis	T062	C0936012
28351298	907	918	significant	T078	C0750502
28351298	919	929	difference	T080	C1705242
28351298	937	953	5-methylcytosine	T114,T123	C0049308
28351298	962	968	normal	T080	C0205307
28351298	973	996	squamous cell carcinoma	T191	C0007137
28351298	997	1004	tissues	T024	C0040300
28351298	1006	1026	area under the curve	T081	C0376690
28351298	1044	1067	5-hydroxymethylcytosine	T109	C0049241
28351298	1068	1074	levels	T080	C0441889
28351298	1081	1087	normal	T033	C0221198
28351298	1089	1121	squamous intraepithelial lesions	T191	C0333873
28351298	1126	1149	squamous cell carcinoma	T191	C0007137
28351298	1151	1159	Analyses	T062	C0936012
28351298	1167	1193	next generation sequencing	T063	C2936622
28351298	1194	1201	results	T169	C1274040
28351298	1206	1210	data	T078	C1511726
28351298	1233	1250	published studies	T170	C1704324
28351298	1269	1275	normal	T033	C0221198
28351298	1280	1322	low-grade squamous intraepithelial lesions	T191	C1302773
28351298	1327	1370	high-grade squamous intraepithelial lesions	T191	C0333875
28351298	1380	1389	malignant	T191	C0006826
28351298	1390	1397	tissues	T024	C0040300
28351298	1398	1408	identified	T080	C0205396
28351298	1420	1424	nine	T081	C0205455
28351298	1425	1430	genes	T028	C0017337
28351298	1432	1439	ARHGAP6	T028	C1412523
28351298	1441	1446	DAPK1	T028	C1413906
28351298	1448	1453	HAND2	T028	C1415467
28351298	1455	1461	NKX2-2	T028	C1417735
28351298	1463	1467	NNAT	T028	C1417747
28351298	1469	1475	PCDH10	T028	C1421975
28351298	1477	1482	PROX1	T028	C1418951
28351298	1484	1489	PITX2	T028	C1418596
28351298	1495	1500	RAB6C	T028	C1424353
28351298	1514	1525	effectively	T080	C1704419
28351298	1526	1538	discriminate	T080	C0205235
28351298	1549	1556	various	T081	C0439064
28351298	1557	1563	groups	UnknownType	C0681860
28351298	1569	1580	sensitivity	T169	C0332324
28351298	1585	1596	specificity	T080	C0205369
28351298	1637	1651	gene promoters	T028	C0314621
28351298	1653	1660	ARHGAP6	T028	C1412523
28351298	1662	1667	HAND2	T028	C1415467
28351298	1669	1673	LHX9	T028	C1422495
28351298	1675	1679	HEY2	T028	C1415525
28351298	1681	1687	NKX2-2	T028	C1417735
28351298	1689	1695	PCDH10	T028	C1421975
28351298	1697	1702	PITX2	T028	C1418596
28351298	1704	1709	PROX1	T028	C1418951
28351298	1711	1715	TBX3	T028	C1420613
28351298	1717	1722	IKBKG	T028	C1416380
28351298	1724	1729	RAB6C	T028	C1424353
28351298	1735	1740	DAPK1	T028	C1413906
28351298	1752	1762	methylated	T044	C0376452
28351298	1785	1800	cervical cancer	T191	C4048328
28351298	1801	1811	cell lines	T025	C0007600
28351298	1812	1818	tested	T169	C0039593
28351298	1824	1830	global	T080	C2348867
28351298	1835	1839	gene	T028	C0017337
28351298	1842	1850	specific	T080	C0205369
28351298	1851	1862	methylation	T044	C0376452
28351298	1879	1884	genes	T028	C0017337
28351298	1885	1895	identified	T080	C0205396
28351298	1903	1908	study	T062	C2603343
28351298	1922	1928	useful	T080	C3827682
28351298	1929	1939	biomarkers	T123	C0041366
28351298	1954	1963	detection	T061	C1511790
28351298	1968	1987	clinical management	T058	C1516615
28351298	1991	2006	cervical cancer	T191	C4048328